OBJECTIVE: To review the evidence regarding treatment of herpes zoster (HZ) in the short-term, focusing on the prevention of postherpetic neuralgia (PHN). QUALITY OF EVIDENCE: The evidence relating to treatment of HZ is derived mainly from randomized controlled trials (level I evidence). MAIN MESSAGE: Antiviral drugs might have some effect on the severity of acute pain and on the duration of skin lesions. Corticosteroids also alleviate acute pain. Oral antiviral medication reduces the risk of eye complications in patients with ophthalmic HZ. There is no convincing evidence that antiviral medication reduces the risk of PHN. Some studies, however, have shown that famciclovir and valacyclovir shorten the duration of PHN. The effectiveness of amitriptyline or cutaneous and percutaneous interventions in preventing PHN has not been proven. CONCLUSION: Oral antiviral drugs should be prescribed to elderly HZ patients with high risk of PHN. Moreover, these drugs should be prescribed to all patients at the first signs of ophthalmic HZ, irrespective of age or severity of symptoms.
OBJECTIVE: To review the evidence regarding treatment of herpes zoster (HZ) in the short-term, focusing on the prevention of postherpetic neuralgia (PHN). QUALITY OF EVIDENCE: The evidence relating to treatment of HZ is derived mainly from randomized controlled trials (level I evidence). MAIN MESSAGE: Antiviral drugs might have some effect on the severity of acute pain and on the duration of skin lesions. Corticosteroids also alleviate acute pain. Oral antiviral medication reduces the risk of eye complications in patients with ophthalmic HZ. There is no convincing evidence that antiviral medication reduces the risk of PHN. Some studies, however, have shown that famciclovir and valacyclovir shorten the duration of PHN. The effectiveness of amitriptyline or cutaneous and percutaneous interventions in preventing PHN has not been proven. CONCLUSION: Oral antiviral drugs should be prescribed to elderly HZ patients with high risk of PHN. Moreover, these drugs should be prescribed to all patients at the first signs of ophthalmic HZ, irrespective of age or severity of symptoms.
Authors: Wim Opstelten; Nicolaas P A Zuithoff; Gerrit A van Essen; Anton M van Loon; Albert J M van Wijck; Cornelis J Kalkman; Theo J M Verheij; Karel G M Moons Journal: Pain Date: 2007-03-26 Impact factor: 6.961
Authors: S Tyring; R Engst; C Corriveau; N Robillard; S Trottier; S Van Slycken; R A Crann; L A Locke; R Saltzman; A G Palestine Journal: Br J Ophthalmol Date: 2001-05 Impact factor: 4.638
Authors: Paul M Coplan; Kenneth Schmader; Alexander Nikas; Ivan S F Chan; Peter Choo; Myron J Levin; Gary Johnson; Mark Bauer; Heather M Williams; Karen M Kaplan; Harry A Guess; Michael N Oxman Journal: J Pain Date: 2004-08 Impact factor: 5.820
Authors: Stephen D Shafran; Stephen K Tyring; Richard Ashton; Jacque Decroix; Chistine Forszpaniak; Alan Wade; Christian Paulet; Daniel Candaele Journal: J Clin Virol Date: 2004-04 Impact factor: 3.168
Authors: Kimberly D Tran; Michelle M Falcone; Daniel S Choi; Raquel Goldhardt; Carol L Karp; Janet L Davis; Anat Galor Journal: Ophthalmology Date: 2016-04-08 Impact factor: 12.079
Authors: Bernhard Ultsch; Ingrid Köster; Thomas Reinhold; Anette Siedler; Gérard Krause; Andrea Icks; Ingrid Schubert; Ole Wichmann Journal: Eur J Health Econ Date: 2012-12-28
Authors: Bernhard Ultsch; Felix Weidemann; Thomas Reinhold; Anette Siedler; Gérard Krause; Ole Wichmann Journal: BMC Health Serv Res Date: 2013-09-26 Impact factor: 2.655
Authors: Carol L Berkower; Nicole M Johnson; Stephen B Longdo; Shenika O McGusty-Robinson; Samantha L Semenkow; Barry J Margulies Journal: Adv Pharmacol Sci Date: 2013-08-04